Drug Concentration Articles & Analysis
17 articles found
This article explores the profound impact of nanotechnology on drug delivery systems and its correlation with formulation development services Enhanced Drug Delivery and Targeting One of the most significant contributions of nanotechnology to pharmaceutical formulations is its ability to enhance drug delivery and targeting. Through the design ...
Pharmacodynamics: The Drug’s Effect on the Body Pharmacodynamics examines the biological and physiological effects of drugs and their mechanisms of action. It focuses on the relationship between drug concentration at the site of action and the resulting therapeutic or toxic response. ...
Role of Liposomes in Drug Delivery The structure of liposomes, consisting of an aqueous core enclosed by a lipid bilayer, allows for the encapsulation of both hydrophilic and lipophilic drugs. ...
Currently, protein drugs are widely used in various fields, including cancer, autoimmune diseases, metabolic diseases, geriatric diseases, and degenerative diseases.In the process of preparing and using recombinant protein drugs, protein concentration analysis is an essential step. The protein concentration can reflect the ...
Ensuring the purity, concentration and conformational stability of the drug is crucial, which not only relates to the efficacy of the drug, but also affects its safety.Ultraviolet spectroscopy technique is based on the absorption characteristics of antibody proteins to specific wavelengths of ultraviolet light, and can provide rapid and ...
Antibody-drug conjugates (ADCs) are a new class of drugs that combine the advantages of both antibodies and small molecule toxins. ...
Conventional liposomes As a drug delivery system, traditional liposomes can change the pharmacokinetic properties and tissue distribution of tumor drugs, enhance the target aggregation concentration of drugs, and enhance drug efficacy. ...
When labeling, the ratio of biotin to antibody is affected by the antibody concentration. When labeling with biotin, the antibody must not contain sodium azide, BSA, glycine, Tris or any other additives with free amino groups. ...
Patient-centric drug development is a divisive concept. Dismissed as a buzzword by some. ...
Once injected into the body, microspheres are gradually degraded in the body, allowing the drug to be released slowly at a certain rate, maintaining the drug concentration in the blood at the site of the lesion, thereby prolonging the half-life of the drug and achieving long-acting sustained release. ...
Advantages of Liposomes as Drug Delivery Vehicles l As drug delivery vehicles, liposomes have low toxicity and immunogenicity, and the high biocompatibility and biodegradability of their components—phospholipids can increase the in vivo drug concentrations and protect drugs from degradation. l They can be ...
Therefore, the effective time of such drugs is short, and the concentration of the drug in the blood changes greatly in a short period of time. ...
At present, SOD mainly has the following two application areas 1. Drugs It is mainly concentrated in patients with inflammatory diseases, especially in the treatment of rheumatoid arthritis, chronic polyarthritis, myocardial infarction, cardiovascular disease, tumor patients, and radiation therapy patients with inflammatory diseases. 2. ...
ADC drugs are composed of three parts: antibody, effector molecule (Payload, usually cytotoxic agent) and linker. Compared with traditional drugs, ADC drugs have obvious advantages in improving targeting and reducing side effects. 1. ...
Therefore, determination of the tissue:plasma partition coefficients (Kp) for organs and tissues is critical because these properties of drug compounds defines their exposure to the specific receptors. Due to differences in Kp values for different organs, drug target exposure may not be directly correlated with general plasma concentration ...
The primary endpoints are freedom from all-cause mortality, target limb major amputation and target lesion revascularization and AlucentNVS drug plasma concentrations. We are also in the process of finalizing the protocol for a larger IDE clinical trial with our intended commercial AlucentNVS system. ...
Rather, they are increasingly relying on small firms for drug discovery, while concentrating on their core competencies for drug development and marketing. ...